C Frank Bennett
Overview
Explore the profile of C Frank Bennett including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
158
Citations
19364
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mathews E, Coffey S, Gartner A, Belgrad J, Bragg R, OReilly D, et al.
bioRxiv
. 2024 Nov;
PMID: 39574582
Huntington's disease (HD) arises from a CAG expansion in the () gene beyond a critical threshold. A major thrust of current HD therapeutic development is lowering levels of mutant mRNA...
2.
Lu C, Chen G, Song W, Chen K, Hee C, Nikan M, et al.
J Am Chem Soc
. 2024 Jul;
146(29):20221-20229.
PMID: 38985464
Nanoscale secondary ion mass spectrometry (NanoSIMS) makes it possible to visualize elements and isotopes in a wide range of samples at a high resolution. However, the fidelity and quality of...
3.
Ecker D, Aiello C, Arron J, Bennett C, Bernard A, Breakefield X, et al.
Nat Rev Drug Discov
. 2024 Feb;
23(5):321-322.
PMID: 38409339
No abstract available.
4.
Lopez-Erauskin J, Bravo-Hernandez M, Presa M, Baughn M, Melamed Z, Beccari M, et al.
Nat Neurosci
. 2023 Nov;
27(1):34-47.
PMID: 37996528
The mRNA transcript of the human STMN2 gene, encoding for stathmin-2 protein (also called SCG10), is profoundly impacted by TAR DNA-binding protein 43 (TDP-43) loss of function. The latter is...
5.
Mummery C, Borjesson-Hanson A, Blackburn D, Vijverberg E, De Deyn P, Ducharme S, et al.
Nat Med
. 2023 Oct;
30(1):304.
PMID: 37845513
No abstract available.
6.
McCauley M, Bennett C
Neuron
. 2023 Jun;
111(16):2465-2468.
PMID: 37354903
The regulatory approvals of nusinersen and tofersen, plus the large body of clinical and preclinical data from other drugs, have significantly de-risked antisense technology for neurological diseases. The platform learnings...
7.
Gleeson J, Bennett C, Carroll J, Cole T, Douville J, Glass S, et al.
Nat Med
. 2023 May;
29(6):1302-1303.
PMID: 37169866
No abstract available.
8.
McMahon M, Rahdar M, Mukhopadhyay S, Bui H, Hart C, Damle S, et al.
Mol Ther Nucleic Acids
. 2023 Apr;
32:289-301.
PMID: 37096163
Antisense oligonucleotides (ASOs) are short synthetic nucleic acids that recognize and bind to complementary RNA to modulate gene expression. It is well established that single-stranded, phosphorothioate-modified ASOs enter cells independent...
9.
Mummery C, Borjesson-Hanson A, Blackburn D, Vijverberg E, De Deyn P, Ducharme S, et al.
Nat Med
. 2023 Apr;
29(6):1437-1447.
PMID: 37095250
Tau plays a key role in Alzheimer's disease (AD) pathophysiology, and accumulating evidence suggests that lowering tau may reduce this pathology. We sought to inhibit MAPT expression with a tau-targeting...
10.
Baughn M, Melamed Z, Lopez-Erauskin J, Beccari M, Ling K, Zuberi A, et al.
Science
. 2023 Mar;
379(6637):1140-1149.
PMID: 36927019
Loss of nuclear TDP-43 is a hallmark of neurodegeneration in TDP-43 proteinopathies, including amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). TDP-43 mislocalization results in cryptic splicing and polyadenylation of...